Previous 10 | Next 10 |
- Commenced 10-year highly strategic partnership with Gilead to deliver next-generation cancer therapies - Recently announced collaboration with AstraZeneca for registrational trial, PACIFIC-8, further validates domvanalimab’s therapeutic potential - Significant...
- Collaboration Further Strengthens Arcus’s Position at the Forefront of the Anti-TIGIT Field and Leverages AstraZeneca’s Leadership in the Curative-Intent Stage III NSCLC Setting - Registrational Trial for Domvanalimab plus Imfinzi Expected to Begin in 2...
Gainers: [[SRRK]] +23.7%. [[SYNL]] +12.3%. [[CYH]] +11.6%. [[FSLR]] +8.8%. [[MSTR]] +7.1%.Losers: [[KTCC]] -12.8%. [[SUM]] -8.7%. [[RCUS]] -8.3%. [[BGFV]] -6.0%. [[APLT]] -5.8%. For further details see: SRRK, SYNL, KTCC and SUM among after-hours movers
Arcus Biosciences (RCUS) announces that Jennifer Jarrett has rejoined Arcus as COO with responsibility for Arcus's commercial and general & administrative organizations, including finance and human resources.Ms. Jarrett has served on RCUS’s board of directors since January 2019 and...
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Jennifer Jarrett has rejoined Arcus as Chief Operating Officer with responsibility for Arcus’s commercial and general & ad...
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management will present at the following upcoming virtual investor conferences: Citi 15 th Annual BioPharma Virtual Conference, Wedn...
Arcus Biosciences (NYSE: RCUS ) : Q2 GAAP EPS of -$0.93 misses by $0.34 . More news on: Arcus Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
‒ Established a 10-year global partnership with Gilead to co-develop and co-commercialize next-generation cancer immunotherapies ‒ Strengthened balance sheet by raising approximately $348 million in gross proceeds from a public offering of Arcus’s common stock ...
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that, as previously disclosed in its Form 8-K filed with the Securities and Exchange Commission on July 7, 2020, the company made an inducement ...
Volatility watch: Short interest is in an uptrend for Vale (NYSE: VALE ) , Nokia (NYSE: NOK ) , United Airlines (NASDAQ: UAL ) , Micron Technology (NASDAQ: MU ) and Denbury Resources (NYSE: DNR ) , while GameStop (NYSE: GME ) , National Beverage (NASDAQ: FIZZ ) and Dillard's (NYSE:...
News, Short Squeeze, Breakout and More Instantly...
Arcus Biosciences Inc. Company Name:
RCUS Stock Symbol:
NYSE Market:
Arcus Biosciences Inc. Website:
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will host a conference call and webcast on Thursday, August 8 th , 2024 at 2 PM...
Arcus Biosciences, Inc. (NYSE:RCUS) and Taiho Pharmaceutical Co., Ltd. (“Taiho”) today announced that Taiho exercised its option for quemliclustat (International Nonproprietary Name; development code: AB680), an investigational small molecule CD73 inhibitor, in Japan and certain oth...
Domvanalimab is the only anti-TIGIT antibody in Phase 3 for upper gastrointestinal (GI) adenocarcinomas with the potential to be first-to-market for this patient population Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing di...